A2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models

• Main Authors: Tay, Apple Hui Min, Prieto-Díaz, Rubén, Neo, Shiyong, Tong, Le, Chen, Xinsong, Carannante, Valentina, Önfelt, Björn, Hartman, Johan, Haglund, Felix, Majellaro, Maria, Azuaje, Jhonny, Garcia-Mera, Xerardo, Brea, Jose M., Loza, Maria I., Jespers, Willem, Gutierrez-de-Teran, Hugo, Sotelo, Eddy, Lundqvist, Andreas
• Other Authors: School of Biological Sciences
• Format: Article
• Language: English
• Published: 2023
• Subjects: Science::Biological sciences; Adenosine; Immunotherapy
• Online Access: https://hdl.handle.net/10356/171035
• Institution: Nanyang Technological University

Adenosine is a metabolite that suppresses antitumor immune response of T and NK cells via extracellular binding to the two subtypes of adenosine-2 receptors, A2ARs. While blockade of the A2AARs subtype effectively rescues lymphocyte activity, with four A2AAR antagonists currently in anticancer clinical trials, less is known for the therapeutic potential of the other A2BAR blockade within cancer immunotherapy. Recent studies suggest the formation of A2AAR/A2BAR dimers in tissues that coexpress the two receptor subtypes, where the A2BAR plays a dominant role, suggesting it as a promising target for cancer immunotherapy.